F2-Isoprostanes Inversely Linked to Diabetes Risk

Significant association for isoprostanes iPF2α-III, 2,3-dinor-iPF2α-III, and iPF2α-VI

FRIDAY, Dec. 2 (HealthDay News) -- Urinary F2-isoprostanes (iPF2α-III, 2,3-dinor-iPF2α-III, and iPF2α-VI) show a significant inverse association with the risk of type 2 diabetes, according to a study published online Nov. 18 in Diabetes Care.

Dora Il'yasova, Ph.D., from the Duke University Medical Center in Durham, N.C., and colleagues examined whether F2-isoprostane levels were inversely associated with type 2 diabetes risk, using the entire Insulin Resistance Atherosclerosis Study cohort. A total of 138 cases with incident type 2 diabetes and 714 non-case individuals were included. Liquid chromatography-tandem mass spectrometry was used to assay four F2-isoprostanes, including iPF2α-III, 2,3-dinor-iPF2α-III, iPF2α-VI, and 8,12-iso-iPF2α-VI, in baseline urine samples.

The investigators found that there was a significant inverse association seen between three F2-isoprostanes and type 2 diabetes risk, with adjusted odds ratios for iPF2α-III, 2,3-dinor-iPF2α-III, iPF2α-VI, and 8,12-iso-iPF2α-VI of 0.52 (95 percent confidence interval [CI], 0.39 to 0.67), 0.56 (95 percent CI, 0.42 to 0.73), 0.62 (95 percent CI, 0.48 to 0.79), and 0.91 (95 percent CI, 0.72 to 1.12), respectively.

"Our findings indicate that urinary F2-isoprostanes are inversely associated with type 2 diabetes risk beyond the traditional risk factors and may be useful in identifying high risk populations," the authors write.

Full Text (subscription or payment may be required)

Copyright © 2011 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events